Literature DB >> 26283467

The outcome of white matter abnormalities in early treated phenylketonuric patients: A retrospective longitudinal long-term study.

Mario Mastrangelo1, Flavia Chiarotti2, Luana Berillo3, Caterina Caputi4, Claudia Carducci5, Claudio Di Biasi6, Filippo Manti7, Francesca Nardecchia8, Vincenzo Leuzzi9.   

Abstract

BACKGROUND: Pathogenesis and clinical consequences of white matter abnormalities on magnetic resonance imaging (MRI) in phenylketonuric (PKU) patients are incompletely known.
OBJECTIVE: To study white matter alterations progression and outcome and its relationships with phenylalanine levels and intelligence quotient (IQ) in early treated PKU subjects who underwent serial MRIs during a prolonged follow-up.
METHODS: 47 early treated PKU patients (mean age 25.1 ± 5.6 years; range 12-37 years) have been enrolled when two or more consecutive brain MRIs, a complete biochemical history, and MRI-concurrent blood phenylalanine levels were available. The severity and extension of white matter abnormalities were expressed in a computed score. Consecutive IQ assessments were available in 24 patients. We analyzed intra- and interindividual white matter alterations variations and their relationship with quality of biochemical control and cognitive outcome.
RESULTS: Early treated PKU patients showed a high rate of white matter alterations with a relevant increase in frequency/severity from the second decade of life onwards. Age and quality of dietary control before or between subsequent examinations showed an independent cumulative effect on white matter alterations outcome. No significant association was found between white matter alterations and cognitive outcome. A remarkable interindividual variability was found and several patients disclosed incongruity between the trajectory of white matter alterations and biochemical control. About 30% of white matter alterations variability remains unexplained by the disease-associated determinants.
CONCLUSIONS: The evolution of white matter alterations is not significantly affected by intellectual outcome and is affected by aging, chronic exposure to phenylalanine, and unknown individual factors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  intellectual outcome in phenylketonuria; intellectual quotient; magnetic resonance; phenylketonuria; white matter outcome in phenylketonuria

Mesh:

Substances:

Year:  2015        PMID: 26283467     DOI: 10.1016/j.ymgme.2015.08.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Predictability and inconsistencies in the cognitive outcome of early treated PKU patients.

Authors:  Filippo Manti; Francesca Nardecchia; Sabrina Paci; Flavia Chiarotti; Claudia Carducci; Carla Carducci; Silvia Dalmazzone; Graziella Cefalo; Elisabetta Salvatici; Giuseppe Banderali; Vincenzo Leuzzi
Journal:  J Inherit Metab Dis       Date:  2017-08-23       Impact factor: 4.982

2.  Altered tetrahydrobiopterin metabolism in patients with phenylalanine hydroxylase deficiency.

Authors:  Francesca Nardecchia; Flavia Chiarotti; Claudia Carducci; Silvia Santagata; Giulia Valentini; Antonio Angeloni; Nenad Blau; Vincenzo Leuzzi
Journal:  Eur J Pediatr       Date:  2017-05-24       Impact factor: 3.183

3.  Improved Measurement of Brain Phenylalanine and Tyrosine Related to Neuropsychological Functioning in Phenylketonuria.

Authors:  Susan E Waisbren; Sanjay P Prabhu; Patricia Greenstein; Carter Petty; Donald Schomer; Vera Anastasoaie; Kalin Charette; Daniel Rodriguez; Sai Merugumala; Alexander P Lin
Journal:  JIMD Rep       Date:  2016-09-28

4.  Plasma metabolomic profile changes in females with phenylketonuria following a camp intervention.

Authors:  Meriah S Schoen; Rani H Singh
Journal:  Am J Clin Nutr       Date:  2022-03-04       Impact factor: 7.045

5.  Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria.

Authors:  Amelie S Lotz-Havla; Sabrina Katzdobler; Brigitte Nuscher; Katharina Weiß; Johannes Levin; Joachim Havla; Esther M Maier
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

6.  White and gray matter brain development in children and young adults with phenylketonuria.

Authors:  Zoë Hawks; Anna M Hood; Dov B Lerman-Sinkoff; Joshua S Shimony; Jerrel Rutlin; Daniel Lagoni; Dorothy K Grange; Desirée A White
Journal:  Neuroimage Clin       Date:  2019-07-02       Impact factor: 4.881

7.  Optical Coherence Tomography to Assess Neurodegeneration in Phenylalanine Hydroxylase Deficiency.

Authors:  Amelie S Lotz-Havla; Katharina Weiß; Katharina Schiergens; Stephanie Regenauer-Vandewiele; Klaus G Parhofer; Tara Christmann; Luise Böhm; Joachim Havla; Esther M Maier
Journal:  Front Neurol       Date:  2021-12-10       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.